Health
Medical
Cancer Prevention

NeoGenomics

$19.72
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.37 (1.91%) Today
+$0.37 (1.91%) Today

Why Robinhood?

You can buy or sell NeoGenomics and other stocks, options, ETFs, and crypto commission-free!

About

NeoGenomics, Inc. provides cancer diagnostics and pharma services. It operates through a network of cancer focused testing laboratories to provide genetic and molecular testing services. Read More It offers various testing services, including Cytogenetics, Fluorescence In-Situ Hybridization, Flow Cytometry, Immunohistochemistry, Molecular testing and Pathology consultation. The company operates through two segments: Clinical Services Segment provides various clinical testing services to community-based pathology practices, hospital pathology labs and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and patients. Pharma Services segment: provides comprehensive testing services in supports pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Employees
1,500
Headquarters
Fort Myers, Florida
Founded
1998
Market Cap
1.83B
Price-Earnings Ratio
307.64
Dividend Yield
0.00
Average Volume
825.83K
High Today
$19.78
Low Today
$19.32
Open Price
$19.49
Volume
85.25K
52 Week High
$20.31
52 Week Low
$7.71

Collections

Health
Medical
Cancer Prevention
Insurance
Pharmaceutical
Finance
US
North America

News

The Motley FoolMar 11

Here's Why Genetic Testing Stocks Rose as Much as 42.9% in February

What happened February was a great month for genetic testing stocks. Shares of Invitae (NYSE:NVTA) paced the pack with a monthly gain of 42.9%, according to data provided by S&P Global Market Intelligence. That was followed by NeoGenomics (NASDAQ:NEO) and Myriad Genetics (NASDAQ:MYGN), which rose 17.9% and 10.1%, respectively. Each stock soared on the heels of impressive quarterly operating results. The industry has long been a source of eye-popping growth, but is now harboring multiple profitable busines...

1,040
MarketBeatMar 2

Stock Price, News, & Analysis for NeoGenomics

NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their ...

38
Simply Wall StFeb 22

Is NeoGenomics, Inc.’s (NASDAQ:NEO) CEO Overpaid Relative To Its Peers?

Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Doug VanOort became the CEO of NeoGenomics, Inc. (NASDAQ:NEO) in 2009. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we’ll look at a snap shot of the business growth. And finally – as a second measure of performance – we will look at the returns shareholders have received over the last few years. This process should give ...

44

Earnings

$0.01
$0.03
$0.04
$0.06
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected Apr 30, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.